Gerresheimer (XTRA:GXI) Resets Its Board And Debt Plan, Is The Stock Fully Valued?
New Supervisory Board and Debt Focus Put Gerresheimer Stock in the Spotlight
Gerresheimer (XTRA:GXI) has drawn investor attention after shareholders elected four new representatives to the Supervisory Board and appointed Markus Sieger as Chairman, alongside a stated focus on debt reduction and comprehensive refinancing.
At a share price of €27.9, Gerresheimer has seen short term momentum pick up, with a 1 day share price return of 1.90% and a 7 day share price return of 9.84%, while the 1 year total shareholder return has declined 35.77%. This suggests recent optimism is emerging against a weak longer term record as investors react to the new Supervisory Board, leadership change and the stated focus on refinancing and debt reduction.
Compare Gerresheimer's recent boardroom shift and refinancing focus with other companies showing similar momentum and balance sheet stories in the list of solid balance sheet and fundamentals (437 results).
So with Gerresheimer stock rebounding in the short term but still down sharply over 1 and 3 years, should you lean into this boardroom reset and debt plan now, or wait for a clearer valuation cushion before stepping in?
Most Popular Narrative: 10% Overvalued
The most followed narrative puts Gerresheimer's fair value at €25.26, below the latest close of €27.90, which frames the current debate around the stock.
The acquisition of Bormioli Pharma is expected to propel Gerresheimer's revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company's adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.
Curious what justifies that fair value cut below today's price. The narrative leans on a mix of moderate revenue growth, margin repair and a future earnings multiple that assumes solid execution without stretching into blue sky territory.
Result: Fair Value of €25.26 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Gerresheimer's reporting delays, accounting concerns and higher leverage tied to the Bormioli Pharma deal could still unsettle confidence in the current narrative of overvaluation.
Find out about the key risks to this Gerresheimer narrative.
Another View On Gerresheimer’s Valuation
The first narrative points to Gerresheimer trading around 10% above an analyst fair value of €25.26. Yet Simply Wall St’s DCF model points to an estimated future cash flow value of €47.37 and suggests the stock is trading about 41.1% below that level. Which lens do you trust more right now?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With sentiment around Gerresheimer clearly split between concern over risks and optimism about potential rewards, it makes sense to review the data yourself and act promptly. To see both sides in one place, start with the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Gerresheimer?
If you stop with Gerresheimer, you risk missing other opportunities. Use the Simply Wall Street screener to compare different return profiles, balance sheets and dividend stories.
- Target potential mispricings by scanning a curated range of companies that look undervalued on quality and fundamentals through the 265 high quality undervalued stocks.
- Strengthen your income stream by checking which high yield opportunities qualify as potential dividend fortresses using the 374 dividend fortresses.
- Reduce portfolio stress by focusing on companies with resilient finances and lower risk scores in the 281 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com